A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body
Conditions
Neoplasms - Neoplasm Metastasis - Melanoma - Carcinoma, Non-Small-Cell Lung - Colorectal Neoplasms
Conditions: official terms
Carcinoma, Non-Small-Cell Lung - Colorectal Neoplasms - Neoplasm Metastasis - Neoplasms
Study Type
Interventional
Study Phase
Phase 1
Study Design
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Intervention
Name: LY3009120 capsule
Type: Drug
Overall Status
Recruiting
Summary
The main purpose of this study is to see how safe the investigational drug known as LY3009120 is and whether it will work to help people with advanced cancer or cancer that has spread to other parts of the body.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- Advanced or metastatic cancer

- Other available therapies have failed to cure the cancer

- The cancer that has no proven effective therapy

- The cancer can be biopsied (depending on the tumor type and/or the dose of drug received, tumor biopsies may be required)

- Able to swallow capsules

Exclusion Criteria:

- Have active cancer in the brain or spinal cord

- Have an active infection of any kind (fungal, viral, or bacterial)

- Have a cancer of the blood

- Are pregnant or breastfeeding

- Have some types of eye problems or impairments
Locations
Pinnacle Oncology Hematology
Scottsdale, Arizona, United States
Status: Recruiting
Contact: - 480-860-5000
Massachusetts General Hospital
Boston, Massachusetts, United States
Status: Recruiting
Contact: - 617-724-4800
Massachusetts General Hospital
Boston, Massachusetts, United States
Status: Recruiting
Contact: - 617-724-4800
University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Status: Recruiting
Contact: - 713-563-5844
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nedlands, Australia
Status: Not yet recruiting
Contact: Eli Lilly and Company
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Villejuif, France
Status: Recruiting
Contact: Eli Lilly and Company
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Barcelona, Spain
Status: Recruiting
Contact: Eli Lilly and Company
Start Date
November 2013
Completion Date
September 2016
Sponsors
Eli Lilly and Company
Source
Eli Lilly and Company
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page